Out-patient Treatment

SERVICES

Out-patient Counselling and Therapeutic Services for Addictive Substance Users:

- the first contact - assessment

- anonymous counselling service

- pre-treatment and motivational counselling

- buprenorphine substitution treatment – psycho-social component of the programme

- after-care

- supported employment

 

Out-patient Counselling and Therapeutic Services for Families in Difficulties:

- counselling services for parents and relatives of drug users, experimenters, and children or adolescents in at-risk environment

- family therapy and counselling

 

TARGET GROUP

- children and youngsters experimenting with addictive substances

- adolescents and young adults abusing addictive substances

- people with addictive substance dependence

- clients of buprenorphine substitution treatment

- people abstaining after out-patient or in-patient therapy (including unfinished therapy)

- families, parents, extended family members, and other close relations of the user

- families with problems connected with risk behaviour of a child (truancy, theft, chicane etc.) 

 

Education for Professionals Offering Psycho-Social Services

  • course of family counselling
  • open interdisciplinary seminars (every month)

Telephone/Internet Information Service and Counselling

 telephone no.:

+420 233 355 459

+420 777 161 138

information service and e-counselling:

www.prevcentrum.cz

 

STAFF

PROFESSIONAL TEAM:

Mgr.Alexandra Roubalová – psychotherapy, family therapy, psychodiagnoses – MD

Mgr.Ondřej Počarovský – family therapy, management

MUDr.Hana Karbanová – family therapy, psychiatric examination

Mgr.Františka Lukáčová – psychotherapy - MD

Mája Vřeská – counseling

Mgr. Lucie Kovandová – social worker

Mgr. Petra Vondráčková – psychotherapy, psychodiagnoses


EXTERNAL CO-OPERATOR

 MUDr. Zuzana Skodova – health service and counselling, prescription of substitution medication

 Guarantor of the buprenorphine substitution programme:MUDr. Zuzana Skodova

Supervisor of individual psychotherapy and group work: PhDr. Martin Hajný

Supervisor of family therapy: PhDr. Alena Palousova

Team supervisor: PhDr. Helena Fišerová

 

CO-OPERATING ORGANIZATIONS

 

Co-operation within Prev-Centrum, NGO:

Primary Prevention Programmes, Prev-Centrum, NGO

Low-threshold Services, Prev-centrum, NGO

 

Co-operation with specialised facilities:

Dr. Vratislav Rehak, hepatologist

Dr. Zuzana Skodova, GP

A-T office, Prague 6

K-centrum Sananim

FN Motol, infectious-disease ward of the hospital

Dr. Alena Palousova, clinical psychologist

Detoxification Centre for Children and Adolescents, Pod Petrinem

In-patient care, therapeutic communities and others

 

Co-operation with local and state administration:

Social Care Departments

Probation and Mediation Service

 

Co-operation with other institutions in the field of professional education

 

FUNDING

  1. Government´s Council for Drug Policy Co-Ordination
  2. Prague City Council
  3. Ministry of Social Affairs
  4. Prev-Centrum´s own financial participation
  5. Prague 6 Administration

 

CONTACT

Address:        Meziškolská 1120/2,

                        169 00 Praha 6

tel./fax:        +420 233 355 459, +420 777 161 138

e-mail:           poradna@prevcentrum.cz

web:              www.prevcentrum.cz

 

OPENING HOURS

 

DAY

TIME

Monday

8:00 – 16:00

Tuesday

8:00 – 16:00

Wednesday

8:00 – 16:00

Thursday

8:00 – 16:00

Friday

8:00 – 16:00

 

BUPRENORPHINE SUBSTITUTION PROGRAMME

 
Structure of the Programme (Main Principles):

- high threshold

- prescription of buprenorphine under the condition of regular attendance to the centre

- relatively fast lowering of the dosages with the objective of stabilization on very low dosages / abstinence

- systematic care – holistic approach (employment services, social counselling, intensive co-operation with physicians etc.)

- group psychotherapy for clients on very low dosages of buprenorphine

 

Phases of the Programme – Main Characteristics

 

Phase 0 – Introductory Phase (4 weeks)

 Procedure: aproxx. 4 - 8 sessions

Objectives: verifying client's indication for the programme and provision of legal buprenorphine (on prescription); psychiatric and psychological assesment

 

Phase I – Motivational Phase (3 months)

 Procedure: case management, individual planning, motivational group (once a week), one-to-one sessions (once a month)

Objectives: stabilising client's situation

 

Phase II – Therapeutic Phase (3 - 24 months)

 Procedure: individual case management meetings / individual psychotherapy

Objectives: client's abstinence from illicit substances, starting changes in client's lives – relationships, free time, lowering the dosages of substitution

 

Phase III – After Care (3 - 12 months)

 Procedure: one-to-one sessions

Objectives: maintaining client's abstinence; changes in client's life style

 

 ADDITIONAL SERVICES - CHARACTERISTIC

 Social Counselling

 - counselling of social-law and labour-law problems

- stabilisation of client's social situation

 

 CO-OPERATION WITH PHYSICIANS:

- information exchange concerning clients' attendance and other substantial circumstances

- prescribing buprenorphine for relatively short periods of time (1 week) – at least in the beginning of the programme

- regular contact with a client

- individual plan – planned decrease of dosages; the date of planned ending of the programme

- informing about changes in client's individual plan

- prescription of buprenorphine after a least one meetings with a counsellor in the centre and on the basis of therapeutic contract

- pause in prescription ("stop") in case of breaking the rules of the programme

 

 TRENDS:

- prescription of buprenorphine and lowering its dosages is just one part of the whole therapeutic process

- objectives change in respect to the phase of the programme – harm-reduction in the beginning; psychotherapy and social rehabilitation in later phases

- importance of social re-integration

- working with partners – users

- the question of timing – when are the clients ready to abstain? -> Maintenance phase on very low dosages (around 2mg buprenorphine a day)